Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Edwards Lifesciences Corporation is a global medical technology company focused on the development and manufacture of innovative therapies for structural heart disease and advanced hemodynamic monitoring. The company operates primarily within the medical devices and cardiovascular healthcare industries, serving hospitals, cardiac centers, and intensive care units worldwide. Its core mission centers on improving patient outcomes through minimally invasive and data-driven cardiovascular solutions.
The company’s primary revenue drivers are its Transcatheter Heart Valve Therapy products, particularly transcatheter aortic valve replacement (TAVR) systems, and its Critical Care monitoring platforms. Edwards Lifesciences is widely recognized for its leadership position in TAVR technology, supported by strong clinical evidence, physician training infrastructure, and long-term hospital relationships. The company was founded in 1958 and evolved significantly after being spun off from Baxter International in 2000, subsequently focusing its strategy exclusively on cardiovascular innovation.
Business Operations
Edwards Lifesciences operates through three primary business segments: Transcatheter Aortic Valve Replacement (TAVR), Surgical Structural Heart, and Critical Care. The TAVR segment is the largest contributor to revenue, driven by products such as the SAPIEN family of transcatheter heart valves. The Surgical Structural Heart segment includes surgical valve replacement and repair technologies, while Critical Care focuses on advanced hemodynamic monitoring systems used in operating rooms and intensive care units.
The company generates revenue through direct sales to hospitals and healthcare systems across domestic and international markets. Edwards Lifesciences controls proprietary valve designs, catheter-based delivery systems, and monitoring technologies, supported by significant internal research and development capabilities. Operations include wholly owned subsidiaries in key markets and manufacturing facilities in the United States and internationally, with no material joint ventures that materially alter consolidated financial results based on publicly available disclosures.
Strategic Position & Investments
Edwards Lifesciences’ strategic direction emphasizes sustained growth in structural heart therapies, expansion into earlier-stage patient populations, and continued innovation in minimally invasive cardiovascular treatments. Growth initiatives include clinical trial investments to broaden indications for existing TAVR platforms and the development of next-generation valve technologies targeting mitral and tricuspid valve disease.
The company has historically pursued selective, technology-driven acquisitions rather than large-scale consolidation, focusing on enhancing its product pipeline and intellectual property portfolio. Investments in digital health capabilities and advanced analytics support its Critical Care segment, while ongoing research initiatives position Edwards Lifesciences in emerging structural heart therapy markets. Public disclosures indicate a disciplined capital allocation strategy centered on organic growth, targeted acquisitions, and shareholder returns.
Geographic Footprint
Edwards Lifesciences is headquartered in the United States, with its principal executive offices located in California. The company maintains a substantial presence in North America, Europe, and Asia-Pacific, with significant commercial operations in Western Europe, Japan, and China. These regions represent key growth markets for transcatheter valve adoption and critical care monitoring solutions.
Manufacturing, research, and commercial infrastructure span multiple continents, enabling localized supply and regulatory responsiveness. International markets account for a substantial portion of total revenue, reflecting the company’s global clinical trial network and long-standing relationships with healthcare providers across developed and emerging economies.
Leadership & Governance
Edwards Lifesciences is led by an experienced executive team with deep expertise in medical technology, clinical research, and global operations. The leadership philosophy emphasizes patient-centric innovation, evidence-based medicine, and long-term value creation through disciplined execution and ethical governance.
Key executives include:
- Bernard Zovighian – Chief Executive Officer
- Scott McCaffrey – Vice President, Investor Relations, Strategy and Corporate Development
- Daveen Hatch – Corporate Vice President, Human Resources
- Bob King – Corporate Vice President, Global Supply Chain and Operations
- Elliot Jones – Chief Financial Officer
The company operates under a governance framework aligned with U.S. public company standards, with oversight provided by an independent board of directors and policies designed to ensure regulatory compliance, transparency, and accountability.